N
Nasimul Ahsan
Researcher at Mayo Clinic
Publications - 45
Citations - 2284
Nasimul Ahsan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 21, co-authored 45 publications receiving 2195 citations. Previous affiliations of Nasimul Ahsan include Rutgers University & Penn State Milton S. Hershey Medical Center.
Papers
More filters
Journal ArticleDOI
Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?
TL;DR: This work examined preoperative creatinine, renal replacement therapy (RRT), incidence of KLTX, and patient survival in the 34 months before and after introduction of MELD and performed a multivariate Cox regression analysis of time to death.
Journal ArticleDOI
Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Christopher P. Johnson,Nasimul Ahsan,Thomas A. Gonwa,Philip F. Halloran,Mark D. Stegall,Mark A. Hardy,Robert A. Metzger,Charles F. Shield,Leslie L. Rocher,John D. Scandling,John Sorensen,Laura L. Mulloy,Jimmy A. Light,Claudia Corwin,Gabriel M. Danovitch,Michael Wachs,Paul VanVeldhuisen,K. Salm,D. Tolzman,William E. Fitzsimmons +19 more
TL;DR: All regimens yielded similar acute rejection rates and graft survival, but the tacrolimus + MMF regimen was associated with the lowest rate of steroid resistant rejection requiring antilymphocyte therapy.
Journal ArticleDOI
Prednisone withdrawal, in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
Nasimul Ahsan,Donald E. Hricik,Arthur J. Matas,Stephen Rose,Stephen J. Tomlanovich,Alan H. Wilkinson,Marian Ewell,Matthew McIntosh,Donald Stablein,Ernest E. Hodge,Daniel H. Hayes,Paul F. Gores,David M. Cohen,Thomas A. Gonwa,Karl Brinler,Robert C. Harland,John F. Neylan,Mark D. Pescovitz,James J. Wynn,Harold C-Yang,William M. Bennett,John B. Copley,John Dunn,S. Tomlanovich,Lawrence Chan,J. Andrew Bertolatus,Mathew R. Weir,Robert Mendez,John D. Pirsch,J. Harold Helderman +29 more
TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.
Journal ArticleDOI
Hepatorenal syndrome: pathophysiology and management.
TL;DR: Despite improved understanding, the prognosis of HRS remained poor, and in the 1970s, the term “terminal functional renal failure” was synonymous with HRS, but knowledge of the pathogenesis and management of H RS has improved greatly.
Journal ArticleDOI
Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Nasimul Ahsan,Nasimul Ahsan,Christopher P. Johnson,Thomas A. Gonwa,Philip F. Halloran,Mark D. Stegall,Mark D. Stegall,Mark A. Hardy,Robert A. Metzger,Charles F. Shield,Leslie L. Rocher,John D. Scandling,John Sorensen,Laura L. Mulloy,Jimmy A. Light,Claudia Corwin,Gabriel M. Danovitch,Michael Wachs,Paul VanVeldhuisen,K. Salm,D. Tolzman,William E. Fitzsimmons +21 more
TL;DR: The combination may provide particular benefit to kidney allograft recipients who develop delayed graft function/acute tubular necrosis and Renal function at 2 years was better in the tacrolimus treatment groups compared with the CsA group.